Citation

Zweifel SA, Saroj N, Shapiro H, Freund KB. Retina 2012; 32(7): 1243-1249.

Affiliation

Department of Ophthalmology, University Hospital Zurich, Zurich, Switzerland.

Copyright

(Copyright © 2012, Ophthalmic Communications Society, Publisher Lippincott Williams and Wilkins)

DOI

10.1097/IAE.0b013e3182469064

PMID

22466461

Abstract

PURPOSE: To investigate whether extremes in visual acuity (very good or very poor) of the fellow eye (FE) influence visual acuity of the study eye in patients receiving intravitreal ranibizumab treatment for neovascular age-related macular degeneration. METHODS: From 2 randomized, controlled, clinical trials (MARINA and ANCHOR), we performed a retrospective analysis of ranibizumab-treated patients who maintained stable FE visual acuity (±5 letters from baseline at each of Months 1, 4, 6, and 12), comparing patients with untreated FE visual acuity that was either 20/32 or better (very good) or 20/200 or worse (very poor). Visual acuity of the treated study eyes, which received monthly intravitreal ranibizumab (0.3 mg or 0.5 mg), was compared between the 2 FE cohorts at the Month 6 and Month 12 visits. RESULTS: A total of 145 patients were analyzed. In the cohort with very poor FE visual acuity (n = 55), there were 35 patients in MARINA and 20 patients in ANCHOR; in the cohort with very good FE visual acuity (n = 90), there were 52 patients in MARINA and 38 patients in ANCHOR.The mean (standard deviation) gain of the study eye visual acuity in the very good FE cohort was 10.3 (13.3) and 10.8 (13.7) letters at Months 6 and 12, respectively, compared with a lesser mean visual acuity gain of 4.6 (12.2) and 6.7 (11.7) letters at Months 6 and 12 in the very poor vision FE cohort. There was no statistically significant difference (adjusted) in the study eye visual acuity change between the 2 cohorts at either 6 months (P = 0.11) or 12 months (P = 0.26). CONCLUSION: This retrospective analysis of the MARINA and ANCHOR study data did not support the hypothesis that FE visual acuity plays a significant role in driving visual acuity of patients receiving monthly intravitreal ranibizumab injections for neovascular age-related macular degeneration. Visual acuity of the FE by itself is, therefore, not a useful parameter in predicting visual acuity in a majority of ranibizumab-treated patients.

Language: en